| Visceral and subcutaneous fat in patients treated with olanzapine: a case series. | |
| | |
MedLine Citation:
|
PMID: 20838214 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome. METHODS: Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glucose, and lipids in an unselected population of 14 schizophrenic patients. RESULTS: We found a 6-week olanzapine treatment to be related to increased body mass index and proportion of total fat at the level of the fourth vertebral body. CONCLUSIONS: On the basis of these findings, we conclude that weight gain after a 6-week olanzapine treatment is partly attributable to increased visceral fat and may thus contribute to metabolic syndrome. |
| | |
Authors:
|
Maria Gilles; Frank Hentschel; Georgios Paslakis; Valerie Glahn; Florian Lederbogen; Michael Deuschle |
Related Documents
:
|
11850754 - The hormone-sensitive lipase gene and body composition: the heritage family study. 15238874 - The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndr... 8742584 - Insulin resistance and body fat distribution. 18492764 - Why are we shaped differently, and why does it matter? 6538624 - Effects of excess dietary cholesterol on adrenal cholesterol accumulation and steroidog... 7980704 - Conjugated linoleic acid and atherosclerosis in rabbits. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 33 ISSN: 1537-162X ISO Abbreviation: Clin Neuropharmacol Publication Date: 2010 Sep-Oct |
Date Detail:
|
Created Date: 2010-09-24 Completed Date: 2011-01-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 248-9 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry and Psychotherapy, and †Neuroradiology, Central Institute of Mental Health, Mannheim, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adiposity Adult Antipsychotic Agents / adverse effects* Benzodiazepines / adverse effects* Body Mass Index Female Humans Intra-Abdominal Fat / drug effects*, radiography Male Metabolic Syndrome X / etiology Schizophrenia / drug therapy Subcutaneous Fat, Abdominal / drug effects*, radiography Tomography, X-Ray Computed Weight Gain / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetia...
Next Document: Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-bli...